Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Briakinumab

Next Previous
X
Search
Drug Profile

Briakinumab

Alternative Names: A-796874.0; ABT-874; Anti-IL-12/23-antibody-Abbott; BSF 415977; J 695; LU 415977; Ozespa; WAY-165772

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Abbott GmbH & Co. KG
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Plaque psoriasis
  • Discontinued Crohn's disease; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 01 Oct 2011 Abbott Laboratories completes a phase III trial in Plaque psoriasis in Canada, Switzerland, USA and the European Union (NCT00626002)
  • 14 Jan 2011 Regulatory submission withdrawn for Plaque psoriasis in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top